These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 17401463)
1. Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression. Kuester D; Dar AA; Moskaluk CC; Krueger S; Meyer F; Hartig R; Stolte M; Malfertheiner P; Lippert H; Roessner A; El-Rifai W; Schneider-Stock R Neoplasia; 2007 Mar; 9(3):236-45. PubMed ID: 17401463 [TBL] [Abstract][Full Text] [Related]
2. Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett's tumorigenesis. Lee OJ; Schneider-Stock R; McChesney PA; Kuester D; Roessner A; Vieth M; Moskaluk CA; El-Rifai W Neoplasia; 2005 Sep; 7(9):854-61. PubMed ID: 16229808 [TBL] [Abstract][Full Text] [Related]
3. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Eads CA; Lord RV; Kurumboor SK; Wickramasinghe K; Skinner ML; Long TI; Peters JH; DeMeester TR; Danenberg KD; Danenberg PV; Laird PW; Skinner KA Cancer Res; 2000 Sep; 60(18):5021-6. PubMed ID: 11016622 [TBL] [Abstract][Full Text] [Related]
4. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression. Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717 [TBL] [Abstract][Full Text] [Related]
5. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus. Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175 [TBL] [Abstract][Full Text] [Related]
6. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions. Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681 [TBL] [Abstract][Full Text] [Related]
8. Promoter methylation of p16, Runx3, DAPK and CHFR genes is frequent in gastric carcinoma. Hu SL; Kong XY; Cheng ZD; Sun YB; Shen G; Xu WP; Wu L; Xu XC; Jiang XD; Huang DB Tumori; 2010; 96(5):726-33. PubMed ID: 21302620 [TBL] [Abstract][Full Text] [Related]
9. Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach. Schildhaus HU; Kröckel I; Lippert H; Malfertheiner P; Roessner A; Schneider-Stock R Int J Oncol; 2005 Jun; 26(6):1493-500. PubMed ID: 15870861 [TBL] [Abstract][Full Text] [Related]
10. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048 [TBL] [Abstract][Full Text] [Related]
11. Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma. Tischoff I; Hengge UR; Vieth M; Ell C; Stolte M; Weber A; Schmidt WE; Tannapfel A Gut; 2007 Aug; 56(8):1047-53. PubMed ID: 17376806 [TBL] [Abstract][Full Text] [Related]
12. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. Bian YS; Osterheld MC; Fontolliet C; Bosman FT; Benhattar J Gastroenterology; 2002 Apr; 122(4):1113-21. PubMed ID: 11910361 [TBL] [Abstract][Full Text] [Related]
13. Risk factors, DNA damage, and disease progression in Barrett's esophagus. Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340 [TBL] [Abstract][Full Text] [Related]
14. Silencing of MGMT expression by promoter hypermethylation in the metaplasia-dysplasia-carcinoma sequence of Barrett's esophagus. Kuester D; El-Rifai W; Peng D; Ruemmele P; Kroeckel I; Peters B; Moskaluk CA; Stolte M; Mönkemüller K; Meyer F; Schulz HU; Hartmann A; Roessner A; Schneider-Stock R Cancer Lett; 2009 Mar; 275(1):117-26. PubMed ID: 19027227 [TBL] [Abstract][Full Text] [Related]
15. Correlation of promoter hypermethylation in hTERT, DAPK and MGMT genes with cervical oncogenesis progression. Iliopoulos D; Oikonomou P; Messinis I; Tsezou A Oncol Rep; 2009 Jul; 22(1):199-204. PubMed ID: 19513524 [TBL] [Abstract][Full Text] [Related]
16. Promoter methylation of death-associated protein kinase and its role in irradiation response in cervical cancer. Leung RC; Liu SS; Chan KY; Tam KF; Chan KL; Wong LC; Ngan HY Oncol Rep; 2008 May; 19(5):1339-45. PubMed ID: 18425396 [TBL] [Abstract][Full Text] [Related]
17. Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma. Agarwal A; Polineni R; Hussein Z; Vigoda I; Bhagat TD; Bhattacharyya S; Maitra A; Verma A Int J Clin Exp Pathol; 2012; 5(5):382-96. PubMed ID: 22808291 [TBL] [Abstract][Full Text] [Related]
18. DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett's adenocarcinoma. Peng DF; Razvi M; Chen H; Washington K; Roessner A; Schneider-Stock R; El-Rifai W Gut; 2009 Jan; 58(1):5-15. PubMed ID: 18664505 [TBL] [Abstract][Full Text] [Related]
19. Effect of methylation-associated silencing of the death-associated protein kinase gene on nasopharyngeal carcinoma. Kong WJ; Zhang S; Guo CK; Wang YJ; Chen X; Zhang SL; Zhang D; Liu Z; Kong W Anticancer Drugs; 2006 Mar; 17(3):251-9. PubMed ID: 16520653 [TBL] [Abstract][Full Text] [Related]
20. p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations. Hardie LJ; Darnton SJ; Wallis YL; Chauhan A; Hainaut P; Wild CP; Casson AG Cancer Lett; 2005 Jan; 217(2):221-30. PubMed ID: 15617840 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]